Amnavero.
← Research directory

Research profile

TB-500

This profile refers to the LKKTETQ fragment of thymosin beta-4. The FDA briefing evaluated a proposed use in wound healing.

  • Limited human evidence
  • Evaluation only
Amnavero TB-500 research vial concept packaging
Amnavero TB-500
Concept packaging

What the research found

FDA staff reviewed evidence about this specific fragment. Results for the full-length thymosin beta-4 protein concern a different molecule.

What remains uncertain

A healing benefit and a safety profile in humans remain unestablished for the fragment.